NEW YORK, Sept. 24, 2020 /PRNewswire/ -- Hoth Therapeutics,
Inc. (NASDAQ: HOTH), a biopharmaceutical company, today
announced completing testing to examine the ability of HT-003 to
block acne pathogenic gene expression in human keratinocytes, the
major cell type of the epidermis and the outermost of the layers of
the skin.
Dr. Jonathan Zippin, M.D., Ph.D., FAAD, Associate Professor
of Dermatology at Weill Cornell Medicine and Hoth Senior Scientific
Advisor, led the first phase of the study. "Thanks to Dr. Zippin
and his team, we have gained insight and gathered significant data
with regards to the significance of HT-003 in blocking acne
pathogenic gene expression," stated Robb
Knie, CEO of Hoth Therapeutics. "We will continue to monitor
the data at lower doses and move onto the testing of rodent skin
and carcinogenesis."
Initial data from the first phase of the research reports that
one of the most critical genes for acne pathophysiology, toll-like
receptor 2 (TLR2), is significantly inhibited by HT-003. In
addition, HT-003 at doses as high as 50 µM led to no observable
toxicity. During the next phase of the research, Dr. Zippin
will identify the minimal effective dose required to block TLR2
signaling in response to a broad range of bacteria derived agonists
to further elucidate the pathway.
"The ability of HT-003 to potently inhibit TLR2 expression
suggests that this drug will not only be effective for acne but may
also help a broad range of patients suffering from disease driven
by over active inflammatory responses to bacteria," stated Dr.
Zippin.
Once HT-003 biomarkers have been identified using thein vitro
human keratinocytes models, testing will move onto into live
rodents.
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc.
is a clinical-stage biopharmaceutical company focused on
developing new generation therapies for dermatological disorders.
Hoth's pipeline has the potential to improve the quality of life
for patients suffering from indications including atopic
dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has
also recently entered into two different agreements to further the
development of two different vaccine prospects to prevent or
treat COVID-19. To learn more, please
visit https://ir.hoththerapeutics.com/.
Forward-Looking Statement
This press release includes
forward-looking statements based upon Hoth's current expectations
which may constitute forward-looking statements for the purposes of
the safe harbor provisions under the Private Securities Litigation
Reform Act of 1995 and other federal securities laws, and are
subject to substantial risks, uncertainties and assumptions. These
statements concern Hoth's business strategies; the timing of
regulatory submissions; the ability to obtain and maintain
regulatory approval of existing product candidates and any other
product candidates we may develop, and the labeling under any
approval we may obtain; the timing and costs of clinical trials,
the timing and costs of other expenses; market acceptance of our
products; the ultimate impact of the current Coronavirus pandemic,
or any other health epidemic, on our business, our clinical trials,
our research programs, healthcare systems or the global economy as
a whole; our intellectual property; our reliance on third party
organizations; our competitive position; our industry environment;
our anticipated financial and operating results, including
anticipated sources of revenues; our assumptions regarding the size
of the available market, benefits of our products, product pricing,
timing of product launches; management's expectation with respect
to future acquisitions; statements regarding our goals, intentions,
plans and expectations, including the introduction of new products
and markets; and our cash needs and financing plans. There are a
number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements.
You should not place reliance on these forward-looking statements,
which include words such as "could," "believe," "anticipate,"
"intend," "estimate," "expect," "may," "continue," "predict,"
"potential," "project" or similar terms, variations of such terms
or the negative of those terms. Although the Company believes that
the expectations reflected in the forward-looking statements are
reasonable, the Company cannot guarantee such outcomes. Hoth may
not realize its expectations, and its beliefs may not prove
correct. Actual results may differ materially from those indicated
by these forward-looking statements as a result of various
important factors, including, without limitation, market conditions
and the factors described in the section entitled "Risk Factors" in
Hoth's most recent Annual Report on Form 10-K and Hoth's other
filings made with the U. S. Securities and Exchange Commission. All
such statements speak only as of the date made. Consequently,
forward-looking statements should be regarded solely as Hoth's
current plans, estimates, and beliefs. Investors should not place
undue reliance on forward-looking statements. Hoth cannot guarantee
future results, events, levels of activity, performance or
achievements. Hoth does not undertake and specifically declines any
obligation to update, republish, or revise any forward-looking
statements to reflect new information, future events or
circumstances or to reflect the occurrences of unanticipated
events, except as may be required by applicable law.
Investor Contact:
LR Advisors
LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download
multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-announces-its-ht-003-shows-positive-initial-data-inhibiting-toll-like-receptor-2-tlr2-301137358.html
SOURCE Hoth Therapeutics, Inc.